Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
29 authors.
Hedieh Jafari *Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio.ORCID 0000-0001-9129-2720
Fiona Brown-Burke *Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio.ORCID 0000-0001-6692-8678
Betsy PrayDivision of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio.ORCID 0000-0001-8629-3454
Shelby SloanDivision of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio.ORCID 0000-0001-7366-9184
JoBeth Helmig-MasonDivision of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio.ORCID 0009-0009-5872-5171
Ian HoutDivision of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio.ORCID 0009-0002-2243-5534
Sydney LeonDivision of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio.ORCID 0009-0008-3937-8736
Mackenzie LongDivision of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio.ORCID 0000-0001-6387-4440
Wing Keung ChanDivision of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio.ORCID 0000-0002-5257-1521
Walter HanelDivision of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio.ORCID 0000-0001-8982-6877
Kara CorpsDepartment of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio.ORCID 0000-0002-5584-6738
Violetta V LeshchenkoDepartment of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0003-2989-0601
Donna EdwardsDepartment of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0009-0006-6749-0413
Ravi Prakash ShuklaDepartment of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0001-7492-5848
Sidorela ReciDepartment of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0009-0006-3923-5132
Paul CollierDepartment of Physiology and Biophysics, Institute for Computational Biomedicine, Weill Cornell Medicine, New York, New York.ORCID 0009-0005-6198-5987
Alessandro La FerlitaDivision of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio.ORCID 0000-0002-3680-3177
Satishkumar SinghDivision of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio.ORCID 0000-0001-9957-9566
Rosario DistefanoDivision of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio.ORCID 0000-0001-7241-7751
Rosa LapalombellaDivision of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio.ORCID 0000-0001-6916-9400
Lalit SehgalDivision of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio.ORCID 0000-0002-1151-5427
Robert B FaryabiDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0002-7931-2175
Cem MeydanDepartment of Physiology and Biophysics, Institute for Computational Biomedicine, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-0663-6216
Christopher E MasonDepartment of Physiology and Biophysics, Institute for Computational Biomedicine, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-1850-1642
Robert A Baiocchi *Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio.ORCID 0000-0002-1619-4853
Samir Parekh *Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0001-9694-8469
Lapo Alinari *Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio.ORCID 0000-0002-8870-4162
Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
Project 3: Targeting PRMT5 in Mantle Cell LymphomaP01CA214274 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI BALLMAN, KARLA V. · 2018 to 2022
$8.9M
Targeting SOX11 in Mantle Cell LymphomaR01CA252222 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI PAREKH, SAMIR, WANG, MICHAEL · 2020 to 2024
$2.8M
Developing novel therapy to improve outcomes in MCLR01CA282483 · NCI · OHIO STATE UNIVERSITY · PI Lalit Sehgal · 2023 to 2026
$1.6M
Center for Strategic Scientific Initiatives, National Cancer Institute (CSSI) R01CA252222NCI NIH HHS P01 CA214274NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA252222NCI NIH HHS R01 CA282483
6 · The paper itself
Abstract
purposeMantle cell lymphoma (MCL) remains incurable despite therapeutic advances, highlighting the need for improved preclinical models. Existing transgenic MCL mouse models have significant limitations, restricting their translational value. EXPERIMENTAL
designWe generated an immunocompetent MCL model by overexpressing the key oncogenic drivers SRY-box transcription factor 11 (SOX11) and Cyclin D1 (CCND1) under the Eµ enhancer in C57BL/6 mice, aiming to replicate human MCL's biological and pathologic features.
resultsEµ-SOX11CCND1 mice developed lymphoma marked by clonal B1a cell expansion in lymphatic and extranodal tissues. Morphologic, immunophenotypic, and transcriptional profiling revealed strong similarity to human MCL, with pathway analysis confirming significant molecular overlap. Importantly, lymphoma cells could be adoptively transferred into wild-type recipients, enabling therapeutic testing within an intact immune system.
conclusionsThe Eµ-SOX11CCND1 mouse represents a robust and biologically relevant model that faithfully recapitulates human MCL. Its immunocompetent nature and adoptive transfer capability make it a valuable model for studying disease mechanisms and evaluating novel therapeutic approaches for patients with MCL.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Novel Immunocompetent Eµ-SOX11CCND1 Mouse Model Phenotypically and Molecularly Resembles Human Mantle Cell Lymphoma. · full record | OpenQuestion